{"id":"da-epoch-r-followed-by-nivolumab","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Rash"},{"rate":"10-30%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL2108738","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DA-EPOCH-R is a chemotherapy regimen that combines etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide. Nivolumab is a monoclonal antibody that targets the PD-1 receptor, preventing the PD-1/PD-L1 interaction and thereby enhancing the immune response against cancer cells.","oneSentence":"DA-EPOCH-R is a chemotherapy regimen that combines etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide, followed by Nivolumab, a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:30:48.086Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma"},{"name":"Classical Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT03620578","phase":"PHASE2","title":"DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2018-08-01","conditions":"Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma","enrollment":97}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Opdivo"],"phase":"phase_2","status":"active","brandName":"DA-EPOCH-R followed by Nivolumab","genericName":"DA-EPOCH-R followed by Nivolumab","companyName":"Stichting Hemato-Oncologie voor Volwassenen Nederland","companyId":"stichting-hemato-oncologie-voor-volwassenen-nederland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DA-EPOCH-R is a chemotherapy regimen that combines etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide, followed by Nivolumab, a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction. Used for Relapsed or refractory diffuse large B-cell lymphoma, Classical Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}